IP Library › Granted Patent US 9,937,073
Granted Patent B2
US 9,937,073 · App. 14/600,505 · Granted Apr 10, 2018

Ocular insert apparatus and methods

Inventors: Eugene de Juan, Jr. (Menlo Park, CA); Yair Alster (Menlo Park, CA); Cary J. Reich (Menlo Park, CA); K. Angela Macfarlane (Menlo Park, CA); Janelle Chang (Menlo Park, CA); Stephen Boyd (Menlo Park, CA); David Sierra (Menlo Park, CA); Jose D. Alejandro (Menlo Park, CA); Douglas Sutton (Menlo Park, CA); Alexander J. Gould (Menlo Park, CA)
Assignee: ForSight Vision5, Inc.
A61F9/0017A61B17/00234A61K9/0051A61L27/025A61L27/16A61K47/34
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,937,073
App. No.
14/600,505
Granted
Apr 10, 2018
Kind
B2
Abstract

A comfortable insert comprises a retention structure sized for placement under the eyelids and along at least a portion of conjunctival sac of the upper and lower lids of the eye. The retention structure resists deflection when placed in the conjunctival sac of the eye and to guide the insert along the sac when the eye moves. The retention structure can be configured in many ways to provide the resistance to deflection and may comprise a hoop strength so as to urge the retention structure outward and inhibit movement of the retention structure toward the cornea. The insert may move rotationally with deflection along the conjunctival sac, and may comprise a retention structure having a cross sectional dimension sized to fit within folds of the conjunctiva. The insert may comprise a release mechanism and therapeutic agent to release therapeutic amounts of the therapeutic agent for an extended time.

Claims (33)

1. An ocular insert for delivering at least one therapeutic agent to an eye for an extended period of time, the insert comprising:

a supporting skeletal structure forming at least an arc of an annulus, the skeletal structure configured to be positioned on the eye outside the cornea of the eye and at least partially underneath at least one of the upper and lower eyelids;

an outer structure encapsulating at least a first portion of the skeletal structure along the arc, the outer structure supported by the skeletal structure, wherein the outer structure is of a durometer that is lower than a durometer of the skeletal structure; and

at least one therapeutic agent provided by the ocular insert;

wherein the ocular insert has a first shape prior to being positioned onto the eye, and the ocular insert conforms in situ after being positioned onto the eye for a period of time, and wherein, upon being removed from the eye, the ocular insert maintains a second shape that is different from the first shape, wherein the skeletal structure determines the first shape and the second shape of the ocular insert.

2. An ocular insert as in claim 1 , wherein the second shape is a shape of at least a portion of an anterior surface of the eye.

3. An ocular insert as in claim 1 , wherein the second shape is a shape of at least a portion of an anterior surface of the eye outside of the cornea.

4. An ocular insert as in claim 1 , wherein the second shape is a shape of at least a region of a fornix of the eye.

5. An ocular insert as in claim 1 , wherein the second shape is a shape of at least a portion of the bony orbit of the eye.

6. An ocular insert as in claim 1 , wherein the ocular insert resists deflection away from the second shape.

7. An ocular insert as in claim 1 , wherein the first shape is annular.

8. An ocular insert as in claim 1 , wherein the first shape is positioned substantially within a first plane and the second shape at least partially extends outside of the first plane.

9. An ocular insert as in claim 1 , wherein the skeletal structure comprises polypropylene.

10. An ocular insert as in claim 9 , wherein the outer structure comprises a silicone material.

11. An ocular insert as in claim 10 , wherein the silicone material comprises the at least one therapeutic agent.

12. An ocular insert as in claim 1 , wherein only the outer structure comprises the at least one therapeutic agent.

13. An ocular insert as in claim 1 , wherein the at least one therapeutic agent comprises a prostaglandin analogue.

14. An ocular insert as in claim 13 , wherein the prostaglandin analogue comprises at least one of bimatoprost, latanoprost, travoprost, and tafluprost.

15. An ocular insert as in claim 1 , wherein the at least one therapeutic agent is for lowering the intraocular pressure of the eye.

16. An ocular insert as in claim 1 , wherein the insert comprises one or more haptics for assisting positioning the insert on the eye.

17. An ocular insert as in claim 1 , wherein the skeletal structure comprises the at least one therapeutic agent provided by the ocular insert.

18. An ocular insert as in claim 1 , wherein the outer structure comprises the at least one therapeutic agent provided by the ocular insert.

19. An ocular insert as in claim 1 , wherein both the skeletal structure and the outer structure comprise the at least one therapeutic agent provided by the ocular insert.

20. An ocular insert as in claim 1 , wherein the skeletal structure is formed of a material selected from the group consisting of polypropylene, nylon, PMMA, polycarbonate, polyethylene terepthalate, polyethylenes, and polyether ether ketone (PEEK).

21. An ocular insert as in claim 1 , wherein the outer structure is formed of a silicone material, polyurethane material, or a hydrogel material.

22. An ocular insert as in claim 1 , wherein the at least one therapeutic agent is configured to treat dry eye.

23. An ocular insert as in claim 22 , wherein the at least one therapeutic agent is a lubricant or a surfactant.

24. An ocular insert as in claim 22 , wherein the at least one therapeutic agent is selected from the group consisting of a non-pharmacologic agent, a lipid, a phospholipid, a fatty alcohol, a fatty acid, an oil, and a silicone oil.

25. An ocular insert as in claim 1 , wherein the skeletal structure has a cross-sectional diameter of between about 0.05 mm and about 0.5 mm and the outer structure has a cross-sectional diameter of about 0.25 mm to about 1.5 mm.

26. An ocular insert as in claim 25 , wherein the skeletal structure is comprised of polypropylene and has a cross-sectional diameter of between about 0.05 mm and about 0.5 mm and the second material is comprised of silicone and has a cross-sectional diameter of about 0.25 mm to about 1.5 mm.

27. An ocular insert as in claim 26 , wherein the silicone has a durometer of at least about Shore A 10 to at least about Shore A 80.

28. An ocular insert as in claim 1 , wherein the skeletal structure is formed to have a self-loading resistance to deflection within a range from about 0.005 N/mm to about 10 N/mm.

29. An ocular insert as in claim 1 , wherein the skeletal structure is formed to have a first self-loading resistance to deflection between about 1 degree and about 60 degrees, wherein the first self-loading resistance to deflection comprises a deflection angle between a first portion of the skeletal structure and a second portion of the skeletal structure when the first portion is supported and held in place and the weight of the second portion deflects the skeletal structure.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 6, 2015
From: DE JUAN, EUGENE, JR.; ALSTER, YAIR; REICH, CARY J.; MACFARLANE, K. ANGELA; CHANG, JANELLE; BOYD, STEPHEN; SIERRA, DAVID; ALEJANDRO, JOSE D.; SUTTON, DOUGLAS; GOULD, ALEXANDER J.
To: FORSIGHT VISION5, INC.
Reel/Frame 036266/0108 →
Continuity (4)
Continuation 13618052 · Sep 14, 2012
Provisional Application 61568624 · Dec 8, 2011
Provisional Application 61534845 · Sep 14, 2011
Related Publication 20150133878A1 · May 14, 2015